Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: The benefit remains uncertain

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2224-2235

  Turner, N H ^a   Partridge, A ^b   Sanna, G ^a   Di Leo, A ^a   Biganzoli, L ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy; Fertility; GNRH analogue; Young age

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; CETRORELIX; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; METHOTREXATE; TAMOXIFEN; TRIPTORELIN;

AMENORRHEA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE EFFECTIVENESS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NONHUMAN; OVARIAN PRESERVATION; OVARIAN RESERVE; OVULATION INDUCTION; PREGNANCY OUTCOME; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; REPRODUCTIVE TOXICITY; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

BREAST CANCER; CHEMOTHERAPY; FERTILITY; GNRH ANALOGUE; YOUNG AGE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; OVARY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84883439197     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt196     Document Type: Review

References (78)

1. National Cancer Institute Surveillance, Epidemiology and End Results: breast cancer incidence and mortality. Available from: www.seer.cancer.gov/statfacts/html/breast.html (11 April 2013, date last accessed).
2. Anders CK, Hsu DS, Broadwater G et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324-3330.
3. Keegan TH, DeRouen MC, Press DJ, et al. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012; 14: R55.
4. Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?. J Clin Oncol 2011; 29: e18-20.
5. Azim HA, Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012; 18: 1341-1351.
6. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogenreceptor- poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371: 29-40.
7. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-444.
8. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004; 13: 295-308.
9. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
10. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769-5779.
11. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008; 26: 753-758.
12. Ruddy KJ, Partridge AH. Fertility (male and female) and menopause. J Clin Oncol 2012; 30: 3705-3711.
13. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002; 8: 141-154.
14. Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007; 96: 1808-1816.
15. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002; 13: 273-279.
16. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-4353.
17. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005; 23: 5155-5165.
18. Ratts VS, Flaws JA, Kolp R, et al. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology 1995; 136: 3665-3668.
19. Tilly JL, Kolesnick RN. Realizing the promise of apoptosis-based therapies: separating the living from the clinically undead. Cell Death Differ 2003; 10: 493-495.
20. Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159-1162.
21. Blumenfeld Z. Preservation of fertility and ovarian function and minimization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002; 187: 93-105.
22. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990; 1: 183-188.
23. Hortobagyi GN, Buzdar AU, Marcus CE et al Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; 1: 105-109.
24. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658.
25. Valagussa P, Moliterni A, Zambetti M,, et al. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res 1993; 127: 247-255.
26. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
27. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002; 9: 466-472.
28. Goodwin PJ, Ennis M, Pritchard KI,, et al.. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-2370.
29. Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist 2012; 17: 1409-1417.
30. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104: 1575-1579.
31. Anderson RA, Cameron DA. Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. J Clin Oncol 2007; 25: 1630-1631. author reply 1632.
32. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
33. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791-798.
34. Swain SM, Jeong JH, Geyer CE, Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
35. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86: 70-80.
36. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril 2010; 93: 391-396.
37. Kim TJ, Laufer LR, Hong SW. Vitrification of oocytes produces high pregnancy rates when carried out in fertile women. Fertil Steril 2010; 93: 467-474.
38. American Society of Reproductive Medicine. http://www.sart.org/news/article. aspx?id=10324 (11 April 2013, date last accessed).
39. Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18: 90-95.
40. Key T, Appleby P, Barnes I,, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616.
41. Pike MC, Spicer DV, Dahmoush L,, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
42. Fisk NM, Templeton AA, Papadopoulos GC et al. Lack of effect of high-dose antioestrogen on the maturation and in-vitro fertilization of human oocytes. Hum Reprod 1989; 4: 584-587.
43. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004; 11: 406-415.
44. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006; 11: 422-434.
45. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20: 783-788.
46. Oktay K, Kim JY, Barad D,, et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28: 240-244.
47. Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006; 100: 59-63.
48. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12: 1044-1054.
49. Oktay K, Sonmezer M, Oktem O, et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12: 1055-1066.
50. Ataya K, Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 1993; 7: 229-235.
51. Ataya K, Rao LV, Lawrence E,, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372.
52. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormonereleasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990; 61: 861-865.
53. Urruticoechea A, Arnedos M, Walsh G, et al. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008; 110: 411-416.
54. Wong M, O'Neill S, Walsh G,, et al. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 2013; 24: 133-138.
55. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Onc 2003; 22: Abstr 50.
56. Maisano R, Caristi N, Mare M, et al. Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study. J Chemother 2008; 20: 740-743.
57. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006; 106: 514-523.
58. Badawy A, Elnashar A, El-Ashry M,, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697.
59. Sverrisdottir A, Nystedt M, Johansson H,, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117: 561-567.
60. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269-276.
61. Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010; 28(15s); Abstr 590.
62. Partridge AH. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?. J Clin Oncol 2012; 30: 479-481.
63. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341.
64. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropinreleasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538.
65. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86.
66. Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA 2011; 306: 312-314.
67. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011; 96: 2532-2539.
68. Visser JA, de Jong FH, Laven JS,, et al. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006; 131: 1-9.
69. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638-644.
70. Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010; 116: 592-599.
71. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008; 26: 286-295.
72. Ruddy K, Gelber S, Tamimi R, et al. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. J Clin Oncol 2012; 30(15s); Abstr 9071.
73. Leonard RC, Adamson D, Bertelli G, et al. The relative value of anti-Mullerian hormone to predict menopause in patients receiving adjuvant chemotherapy for breast cancer: results from the OPTION trial. J Clin Oncol 2012; 30(15s); Abstr 1094.
74. Giraudi S, Marroni P, Boni L, et al. Anti-mullerian hormone (AMH) and ovarian function in young breast cancer (BC) women receiving adjuvant chemotherapy (CT). J Clin Oncol 2009; 27(suppl); Abstr e11544.
75. Fanchin R, Schonauer LM, Righini C, et al. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003; 18: 323-327.
76. Fanchin R, Taieb J, Lozano DH, et al. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005; 20: 923-927.
77. La Marca A, Stabile G, Artenisio AC,, et al. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21: 3103-3107.
78. Lee S, Ozkavukcu S, Heytens E, et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010; 28: 4683-4686.